Public Employees Retirement Association of Colorado Sells 593 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Public Employees Retirement Association of Colorado reduced its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 13.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,726 shares of the company’s stock after selling 593 shares during the period. Public Employees Retirement Association of Colorado’s holdings in TransMedics Group were worth $561,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Amalgamated Bank increased its stake in TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after buying an additional 70 shares during the last quarter. Pitcairn Co. increased its position in shares of TransMedics Group by 1.5% during the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after acquiring an additional 78 shares during the last quarter. Signaturefd LLC lifted its holdings in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the period. Arizona State Retirement System boosted its position in TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after purchasing an additional 186 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in TransMedics Group in the 2nd quarter valued at $47,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Needham & Company LLC assumed coverage on TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price on the stock. Oppenheimer lifted their price objective on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 target price for the company. Stephens lifted their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Robert W. Baird assumed coverage on TransMedics Group in a report on Tuesday. They set an “outperform” rating and a $200.00 price objective for the company. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average target price of $174.30.

TransMedics Group Stock Down 2.5 %

TransMedics Group stock opened at $144.56 on Friday. The firm has a 50 day simple moving average of $156.02 and a 200 day simple moving average of $130.77. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37. The firm has a market capitalization of $4.82 billion, a price-to-earnings ratio of -425.18 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. During the same period in the previous year, the business earned ($0.03) earnings per share. The firm’s quarterly revenue was up 117.7% compared to the same quarter last year. On average, analysts predict that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The disclosure for this sale can be found here. Insiders sold 61,247 shares of company stock valued at $9,650,880 in the last quarter. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.